2026 Global: Age-Related Mascular Degeneration-Competitive Review (2032) report
Description
The 2026 Global: Age-Related Mascular Degeneration-Competitive Review (2031) report features the global market size and projected growth/decline data for the period 2021 through 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for age-related mascular degeneration by geography and historical trend. The scope of the report extends to sizing of the age-related mascular degeneration market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The ten major companies leading the Age-related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Apellis Pharmaceuticals, Astellas Pharma Inc., Amgen Inc., Biogen, Teva Pharmaceutical Industries Ltd., and Boehringer Ingelheim. These firms dominate through approved anti-VEGF therapies for wet AMD and emerging treatments for dry AMD, including complement inhibitors and gene therapies. Regeneron spearheads with Eylea and Eylea HD, high-dose formulations reducing injection frequency for wet AMD patients via innovative platforms like TRAPS and VelociSuite. Bayer partners on Eylea distribution, securing FDA approval for neovascular AMD, while Roche markets Lucentis (ranibizumab) and Vabysmo, expanding into sustained-release implants like Susvimo. Novartis advances Beovu (brolucizumab) and phase 3 gene therapies, operating in over 130 countries with outcome-based pricing.
Apellis Pharmaceuticals targets geographic atrophy in dry AMD with complement inhibitors, alongside Astellas Pharma's IZERVAY (avacincaptad pegol), which gained FDA-expanded labeling in 2025 for flexible dosing. Amgen pursues phase 3 candidates like RTH258 for neovascular AMD, leveraging its biopharmaceutical expertise across 100 countries. Biogen contributes biosimilars and retinal therapies, while Teva provides affordable generics, enhancing accessibility amid rising AMD prevalence projected to affect 22 million Americans by 2050. Boehringer Ingelheim collaborates on retinal pipelines, including inflammasome inhibitors for AMD, diabetic retinopathy, and macular edema, bolstering phase 3 efforts. These companies drive innovation through mergers, like Merck's EyeBio acquisition for Restoret, and trials for AAV gene therapies and RPE cell replacements.
Pipeline advancements underscore their dominance, with over 70 firms in dry AMD trials, but these ten lead commercialization. Stealth BioTherapeutics, Kodiak Sciences, and Outlook Therapeutics trail in phase 3, yet Regeneron, Roche, and Novartis hold market share via Lucentis, Eylea, and Beovu. Recent FDA fast tracks, such as SAR446597 gene therapy in 2025, and Cognition Therapeutics' zervimesine phase 2 data highlight momentum, though early interventions for intermediate dry AMD remain key unmet needs. Global operations span the US, Europe, Asia, and India, with collaborations accelerating R&D from preclinical to post-market surveillance, addressing an aging population's 30% risk over age 75. These leaders prioritize durable therapies, reducing treatment burdens and expanding into glaucoma and optogenetics for sustained growth.
Perry/Hope Partners' reports provide the most accurate industry forecasts based on our proprietary economic models. Our forecasts project the product market size nationally and by regions for 2021 to 2032 using regression analysis in our modeling. and Perry/Hope is the only market research publisher that utilizes both longitudinal (historical) and vertical (from market section to market division to market class) analysis, since we study every manufactured product in the countries we analyze. The report also provides written analysis on the market definition, market segments, and SWOT analysis (market strengths, weaknesses, opportunities, and threats).
The market study aims at estimating the market size and the growth potential of this market. Topics analyzed within the report include a detailed breakdown of the global markets for age-related mascular degeneration by geography and historical trend. The scope of the report extends to sizing of the age-related mascular degeneration market and global market trends with market data for 2024 as the base year, 2025 and 2026 as the estimate years with projection of CAGR from 2027 to 2032.
The report also features a list of the top ten largest global players in the market. A review of each company includes 1) an estimate of the market share, 2) a listing of the products and/or services in the market, and 3) the features of these products and/or services in the market. The report has a chapter on Comparative Business Strategies for the largest four players. An example of the Comparative Business Strategies analysis would be -- How does Netflix's business strategy to expand its market share in the global online streaming compare to Amazon Prime's business strategy through its video products and services?
The ten market players in this report and a brief synopsis of their participation in the market are:
The ten major companies leading the Age-related Macular Degeneration (AMD) market are Regeneron Pharmaceuticals Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, Apellis Pharmaceuticals, Astellas Pharma Inc., Amgen Inc., Biogen, Teva Pharmaceutical Industries Ltd., and Boehringer Ingelheim. These firms dominate through approved anti-VEGF therapies for wet AMD and emerging treatments for dry AMD, including complement inhibitors and gene therapies. Regeneron spearheads with Eylea and Eylea HD, high-dose formulations reducing injection frequency for wet AMD patients via innovative platforms like TRAPS and VelociSuite. Bayer partners on Eylea distribution, securing FDA approval for neovascular AMD, while Roche markets Lucentis (ranibizumab) and Vabysmo, expanding into sustained-release implants like Susvimo. Novartis advances Beovu (brolucizumab) and phase 3 gene therapies, operating in over 130 countries with outcome-based pricing.
Apellis Pharmaceuticals targets geographic atrophy in dry AMD with complement inhibitors, alongside Astellas Pharma's IZERVAY (avacincaptad pegol), which gained FDA-expanded labeling in 2025 for flexible dosing. Amgen pursues phase 3 candidates like RTH258 for neovascular AMD, leveraging its biopharmaceutical expertise across 100 countries. Biogen contributes biosimilars and retinal therapies, while Teva provides affordable generics, enhancing accessibility amid rising AMD prevalence projected to affect 22 million Americans by 2050. Boehringer Ingelheim collaborates on retinal pipelines, including inflammasome inhibitors for AMD, diabetic retinopathy, and macular edema, bolstering phase 3 efforts. These companies drive innovation through mergers, like Merck's EyeBio acquisition for Restoret, and trials for AAV gene therapies and RPE cell replacements.
Pipeline advancements underscore their dominance, with over 70 firms in dry AMD trials, but these ten lead commercialization. Stealth BioTherapeutics, Kodiak Sciences, and Outlook Therapeutics trail in phase 3, yet Regeneron, Roche, and Novartis hold market share via Lucentis, Eylea, and Beovu. Recent FDA fast tracks, such as SAR446597 gene therapy in 2025, and Cognition Therapeutics' zervimesine phase 2 data highlight momentum, though early interventions for intermediate dry AMD remain key unmet needs. Global operations span the US, Europe, Asia, and India, with collaborations accelerating R&D from preclinical to post-market surveillance, addressing an aging population's 30% risk over age 75. These leaders prioritize durable therapies, reducing treatment burdens and expanding into glaucoma and optogenetics for sustained growth.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.